Abstract:Objectives: Polymyxins are the last-line therapy for top-priority multidrug-resistant (MDR) gram-negative bacteria. However, polymyxin nephrotoxicity impedes its clinical application. This study aimed to design, synthesize, and identify a novel and promising polymyxin derivative with high efficacy and low toxicity. Methods: To design polymyxin derivatives, we reduced the hydrophobicity of the two hydrophobic domains (fatty acyl chain and D-Phe6-L-Leu7) and modified the positive charged L-2,4-diaminobutyric acid (Dab) residues. Twenty-five derivatives were synthesized, and their antibacterial activities in vitro and renal cytotoxicities were determined. The nephrotoxicity and pharmacokinetic parameters of compound 12 were examined in rats. Antibacterial efficacy in vivo was evaluated using a mouse systemic infection model. Surface plasmon resonance analysis, compound 12-rifampicin combination therapy, and scanning electron microscopy were used to study the mechanism of action of compound 12. Results: This research found a new compound, identified as compound 12, which showed similar or increased antibacterial activity against all tested sensitive and carbapenem-resistant gram-negative bacteria. It exhibited reduced renal cytotoxicity and nephrotoxicity, a favorable pharmacokinetic profile, and maintained or improved antibacterial efficacy in vivo. Importantly, its anti-Pseudomonas aeruginosa activity significantly improved. Compound 12, when combined with rifampicin, enhanced the activity of rifampin against gram-negative bacteria. Compound 12 also showed a high affinity for lipopolysaccharide and disrupted cell membrane integrity. Conclusion: Reducing the hydrophobicity of the two domains reduced renal cytotoxicity and nephrotoxicity. Shortening the side chain of Dab3 by one carbon maintained or increased its antibacterial activity both in vitro and in vivo. Furthermore, only the length of the side chain of Dab9 could be shortened by one carbon among the Dab1,5 and Dab8,9 residues. The bactericidal effects of compound 12 were related to the disruption of cell membrane integrity. Compound 12 may be a promising candidate for combating sensitive and carbapenem-resistant gram-negative bacterial infections, especially Pseudomonas aeruginosa.

Identification of Novel Potent Bicyclic Peptide Deformylase Inhibitors.

New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment

Toward More Selective Antibiotic Inhibitors: A Structural View of the Complexed Binding Pocket of E. coli Peptide Deformylase

Expression, Purification, and Activity Assay of Peptide Deformylase from Escherichia Coli and Staphylococcus Aureus.

Peptide deformylase inhibitors of Mycobacterium tuberculosis: Synthesis, structural investigations, and biological results

Recent progress in peptide deformylase and its inhibitors

Characterization of Peptide Deformylase Homologues from Staphylococcus Epidermidis

Exploration of Novel Macrocyclic Dipeptide N-benzyl Amides As Proteasome Inhibitors.

Peptide Deformylase is a Potential Target for Anti-Helicobacter Pylori Drugs: Reverse Docking, Enzymatic Assay, and X-ray Crystallography Validation.

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

3D-QSAR and Molecular Docking Studies of Hydroxamic Acids As Peptide Deformylase Inhibitors

PP-003 Evaluation on the cellular immunity of M. tuberculosis in HIV/AIDS and tuberculosis co-infected individuals in China

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Novel Potent 2,5-Pyrrolidinedione Peptidomimetics As Aminopeptidase N Inhibitors. Design, Synthesis and Activity Evaluation

Unique structural characteristics of peptide deformylase from pathogenic bacterium Leptospira interrogans.

Isolation and identification of FR198248, a hydroxylated 1,3-dihydroisobenzofuran, from Aspergillus flavipes as an inhibitor of peptide deformylase

H-Phosphonate Derivatives As Novel Peptide Deformylase Inhibitors

Novel Cyclic-Imide Peptidomimetics As Aminopeptidase N Inhibitors. Structure-Based Design, Chemistry and Activity Evaluation. Ii

Design, synthesis, and bioactivity investigation of novel cyclic lipopeptide antibiotics targeting top-priority multidrug-resistant gram-negative bacteria

Discovery and chemical optimisation of a Potent, Bi-cyclic (Bicycle ) Antimicrobial Inhibitor of PBP3

Design and Synthesis of Novel Chloramphenicol Amine Derivatives As Potent Aminopeptidase N (APN/CD13) Inhibitors